Value through InnovationJanuary 27 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10
01.21.2015

SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States

01.14.2015

Boehringer Ingelheim and Vanderbilt University join forces
to develop new Ras inhibitors for cancer treatment

01.13.2015

Boehringer Ingelheim and Yale University collaborate to investigate novel immunotherapy targets across several therapeutic areas

01.12.2015

The Lancet Oncology publishes phase III data showing Gilotrif® (afatinib) extends overall survival in lung cancer patients whose tumors have the most common EGFR mutation compared with chemotherapy

12.08.2014

New Data Show Idarucizumab* Reverses Anticoagulant Effects of Dabigatran (PRADAXA®) in Middle-Aged, Elderly and Renally Impaired Volunteers

11.20.2014

Boehringer Ingelheim Receives Perfect Rating on Human Rights Campaign Foundation’s Corporate Equality Index

11.19.2014

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

11.18.2014

Interim Data Reinforce Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) versus Warfarin in Routine Care of Patients with Non-valvular Atrial Fibrillation

11.18.2014

New Data Show Idarucizumab* Restores Wound-Site Formation of Fibrin, a Key Component of Blood Clotting, in Healthy Volunteers Given Pradaxa® (dabigatran etexilate mesylate)

11.17.2014

New Survey Uncovers Critical Need to Break Down Barriers and Improve Communication and Education about the Link between Atrial Fibrillation and Devastating Impact of Stroke

back 1 2 3 4 5 6 7 8 9 10